HGT Law Commences a Second Securities Fraud Action Against Valeant Pharmaceuticals and its Senior Officers on Behalf of Retail Investors

On January 19, 2018, HGT Law commenced a second shareholder “opt-out” lawsuit (“Lawsuit”) on behalf of a group of retail investors (“Investors”) against Valeant Pharmaceuticals International, Inc. (“Valeant”) and its senior officers for violations of federal securities laws.  Previously, on June 24, 2016, a class action complaint was filed in the U.S. District Court for the District of New Jersey, on behalf of a class consisting of all purchasers of the common stock of Valeant (“Class Action”).  The Investors have opted out of the Class Action to directly pursue their own claims.  To date, this Lawsuit is the only opt-out action that has been filed on behalf of retail investors.

The Lawsuit is the second one that HGT Law has filed against Valeant.  For more information about the case and the previous opt-out lawsuit commenced against Valeant, see HGT Law Commences Securities Fraud Action Against Valeant Pharmaceuticals and its Senior Officers.

A copy of the complaint filed by HGT Law on behalf of the Investors can be found here.  For more information on opt-out lawsuits, see our publication here.

For more information on how to join the opt-out lawsuit against Valeant, please contact us at (646) 453-7288 or via email at info@hgtlaw.com.